This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "osteoporosis_bone_resorption#Increased Osteoclastic Bone Resorption"). Conforming nodes should substitute the disorder-specific driver of the remodeling imbalance: estrogen deficiency in postmenopausal osteoporosis, Wnt/Dkk1 suppression in glucocorticoid-induced osteoporosis, and LRP5/WNT1 or COL1A1/COL1A2 variants in monogenic low-bone-mass disorders.
The "Endosteal Vascular Niche Dysfunction" node is a deliberately separate, EMERGING upstream arm (hypothesis group endosteal_vascular_niche_model). It is not part of the settled RANKL/Wnt chain and should not be treated as such: a disorder node should declare conformance to it only when there is a specific endothelial or vascular-smooth-muscle lesion in bone, not merely because the disorder features low bone mass.
Endosteal Vascular Niche Contribution to Bone Turnover
endosteal_vascular_niche_model
EMERGING
Evidence: 3
Evidence balance
3 support
An emerging model in which endothelial cells and vascular smooth muscle cells of the endosteal compartment are themselves regulators of bone mass, rather than passive supporting tissue, so that a primary vascular lesion can drive remodeling imbalance and low bone mass. The evidence base is a cross-species single-cell map of the murine endosteal compartment integrated with a human bone mineral density GWAS, functional validation in over 1,000 single-gene-deletion mouse lines, and confirmation of the same cell populations and effector genes in adult human bone. It is curated as EMERGING rather than CANONICAL because the causal demonstrations are in mouse and zebrafish, and no human disorder has yet been shown to produce low bone mass through a demonstrated bone-vascular lesion. Edges belonging to this group carry hypothesis_groups endosteal_vascular_niche_model; a conforming disorder entry should copy the grouping only if its own vascular causal claim belongs to this model.
Do endothelial and vascular smooth muscle lesions in the endosteal compartment cause low bone mass in humans, or do the vascular gene programs score as skeletally relevant because they share genes with the osteoblast lineage?
KNOWLEDGE GAP
OPEN
endosteal_vascular_arm_causal_status
Attached to:
Endosteal Vascular Niche Dysfunction
The enrichment signal that motivates this arm is not uniform across analyses, and the discrepancies point the same way. In the rare-disorder gene enrichment, endothelial and vascular smooth muscle programs reached only nominal significance and the authors themselves attribute that to genes shared with osteoblasts. In the mouse abnormal-bone-structure enrichment, vascular smooth muscle cells were highly enriched but endothelial cells were not. So the two vascular cell types are not equally supported, and the endothelial arm in particular rests on the bone mineral density GWAS enrichment plus single-gene knockouts rather than on monogenic human disease genes. Curators should not upgrade this arm to CANONICAL, and should not let a conforming disorder entry assert a vascular cause of low bone mass on the strength of this module alone.
Proposed experiments:
Endothelial- and VSMC-restricted conditional deletion of validated effector genes
Human bone vascular phenotyping in PLS3-related X-linked osteoporosis
How far does a single-cell map of the mouse endosteal compartment, and functional validation in mouse and zebrafish, transfer to the human endosteal niche?
HUMAN MODEL MISMATCH
OPEN
endosteal_map_species_mismatch
Attached to:
Endosteal Vascular Niche Dysfunction
The cell map and every causal experiment behind this arm are murine or zebrafish; the human component is a bone mineral density GWAS and a single-cell survey of adult human femoral bone. The mouse route was chosen precisely because human endosteal cells are hard to obtain, so the human reference tissue is not equivalent - it is adult femoral head bone from a surgical population, not the metaphyseal and diaphyseal endosteum that was dissected in mouse. The correspondence that was demonstrated is at the level of cell populations and gene expression, which is weaker than a demonstration that the same causal chain operates. This is recorded as HUMAN_MODEL_MISMATCH rather than KNOWLEDGE_GAP because the evidence exists and is strong in the model system; what is open is its translational validity.
Proposed experiments:
Single-cell profiling of the human endosteal compartment
Pls3-deficient mouse (Pls3 hemizygous null, male)
Male mice hemizygous for a Pls3 null allele. PLS3 loss-of-function variants cause osteogenesis imperfecta and X-linked osteoporosis in children, and Pls3 is expressed in osteoblast lineage cells, endothelial cells and vascular smooth muscle cells in bone. The model was used to ask which of those cell types Pls3 acts through, and revealed a bone vascular phenotype rather than a purely osteoblast-intrinsic one.
Genotype
Pls3 hemizygous null (Pls3y/-)
Pathograph links
Endosteal Vascular Niche Dysfunction
recapitulates
fidelity: moderate
Loss of a gene that causes human X-linked osteoporosis produces abnormal bone vasculature, which is the observation this node is built on.
Limitations: The vascular phenotype has been demonstrated in mouse only; individuals carrying PLS3 loss-of-function variants have not been shown to have abnormal bone vasculature, and the authors state the human inference as "might result from". The model is male hemizygous, matching the X-linked human genetics but giving no information about heterozygous carriers. Pls3 is expressed in osteoblast lineage cells as well as in the vasculature, so the model does not by itself isolate the vascular contribution.
Readouts
Bone blood vessel size
Anti-CD31 immunohistochemistry of mid-femur sections with confirmation by backscattered scanning electron microscopy and micro-CT.
Direction: DECREASED
Interpretation: Smaller bone blood vessels are the structural correlate of the vascular niche node in this model.
Evidence: 1
Evidence: 1
pls3 crispant zebrafish embryo
Zebrafish embryos in which pls3 was knocked down, examined at a developmental stage before bone cells are present. This is the experiment that separates a direct vascular role for pls3 from a secondary consequence of a bone defect.
Genotype
pls3 CRISPR-Cas9 crispant (F0 knockdown)
Pathograph links
Endosteal Vascular Niche Dysfunction
perturbs
fidelity: low
Perturbs the same gene in a system with no bone, isolating the vascular patterning function from any skeletal contribution.
Limitations: Zebrafish embryos have no endosteal compartment and no bone at the stage examined, so this model speaks to a general vascular patterning role for pls3 rather than to the endosteal niche specifically. Intersegmental vessel defects in the trunk are not bone vasculature. F0 crispants are mosaic.
Readouts
Intersegmental vessel patterning
Scoring of intersegmental vessel formation in pls3 crispant embryos.
Direction: ALTERED
Interpretation: Disconnections, ectopic connections and smaller lumens indicate a vascular patterning requirement for pls3 that is independent of bone.
Evidence: 1
Nherf2 knockout mouse
Constitutive knockout of Nherf2, an estimated bone mineral density-associated gene whose expression in the endosteal compartment is restricted to endothelial cells. One of over 1,000 single-gene-deletion lines phenotyped for skeletal structure and strength in this study.
Genotype
Nherf2 homozygous knockout (Nherf2-/-)
Pathograph links
Endosteal Vascular Niche Dysfunction
perturbs
fidelity: moderate
Deletes an endothelial-restricted effector gene and produces reduced trabecular bone, which is the functional test of the endothelial arm of this node.
Limitations: The knockout is constitutive, not endothelium-restricted, and Nherf2 is expressed in endothelial cells of other tissues, so a systemic or extraskeletal route to the bone phenotype is not excluded. Bone strength and stiffness were unchanged, so the structural deficit did not translate into a measured mechanical deficit. Only female mice were phenotyped, against a female wild-type reference range, so sex-specificity of the effect is untested.
Readouts
Femoral trabecular bone volume fraction and trabecular number
Micro-CT of distal femur trabecular bone against a wild-type reference range from an identical genetic background.
Direction: DECREASED
Interpretation: Loss of trabecular bone on deletion of an endothelium-restricted gene is the functional evidence that the endothelial compartment contributes to bone mass.
Evidence: 1
Evidence: 1
Cbx6 knockout mouse
Constitutive knockout of Cbx6, an estimated bone mineral density-associated gene whose expression in the skeleton is restricted to vascular smooth muscle cells. Phenotyped for skeletal structure and strength alongside the other effector-gene deletion lines.
Genotype
Cbx6 homozygous knockout (Cbx6-/-)
Pathograph links
Endosteal Vascular Niche Dysfunction
perturbs
fidelity: moderate
Deletes a vascular smooth muscle-restricted effector gene and produces reduced cortical thickness and reduced bone strength, the functional test of the smooth-muscle arm of this node.
Limitations: The knockout is constitutive and Cbx6 is also expressed in lung, brain, pancreas and stomach, so a systemic contribution is not excluded. Only two knockout animals were phenotyped, against a large wild-type reference range, so the effect size is weakly constrained. Only female mice were phenotyped, against a female wild-type reference range, so sex-specificity of the effect is untested.
Readouts
Femoral bone mineral content and cortical thickness
X-ray microradiography and micro-CT of femur and caudal vertebrae, with three-point bending for strength.
Direction: DECREASED
Interpretation: A cortical and strength deficit on deletion of a smooth-muscle-restricted gene is the functional evidence for the vascular smooth muscle arm.
Evidence: 1
Evidence: 1
Endosteal Vascular Niche Dysfunction
trigger
The endosteal compartment, at the interface between bone and bone marrow, is the site where bone turnover is regulated, and it contains vascular endothelial cells (sinusoidal, arteriolar and type H) and vascular smooth muscle cells and pericytes alongside the osteoblast, chondrocyte and osteoclast lineages. Cross-species single-cell mapping of this compartment prioritized endothelial cells and vascular smooth muscle cells as skeletal-disease-relevant cell types whose gene programs are enriched for genes associated with estimated bone mineral density, and predicted that they can signal directly to osteoblast lineage cells. Under this emerging model, a lesion in the endosteal vasculature is an upstream driver of remodeling imbalance in its own right, parallel to the hormonal, pharmacological and osteoblast-intrinsic genetic drivers that dominate the rest of this module.
Downstream
-
Bone Remodeling Imbalance
A vascular lesion in the endosteal niche is proposed to act upstream of the remodeling cycle, shifting the resorption/formation balance without an osteoblast- or osteoclast-intrinsic primary defect.
-
Impaired Osteoblastic Bone Formation
Endothelial and vascular smooth muscle cells are predicted to signal directly to osteoblast lineage cells (NOTCH with endothelium, IGF1R with smooth muscle, TGF-beta in common), so loss of that input would be the most direct route from a vascular lesion to a deficient formation arm. The interaction itself is in-silico (CellPhoneDB) and has not been confirmed by a wet-lab ligand-receptor experiment.
Show evidence (5 references)
"Endothelial cells and vascular smooth muscle cells were identified as new skeletal-disease-relevant cells alongside osteoblast, chondrocyte and osteoclast cell lineages."
The headline claim that establishes this node: endothelial cells and vascular smooth muscle cells are skeletal-disease-relevant lineages in their own right, not only supporting tissue.
"Osteoclasts, osteoblast lineage cells, chondrocytes, ECs and VSMCs originated almost exclusively (> 98%) from this compartment."
Localizes the vascular cell types of this node to the endosteal compartment, which is why the node is scoped to the endosteum rather than to bone vasculature in general.
"VSMC clusters included smooth muscle cells (SMCs) (Myl9+/Acta2+) and pericytes expressing H2-M9 and Rgs5."
Names pericytes as a resolved cluster within the endosteal VSMC compartment, which is the basis for listing CL:0000669 pericyte among this node's cell types.
+ 2 more references
Bone Remodeling Imbalance
trigger
The bone remodeling cycle normally tightly couples osteoclastic resorption to osteoblastic formation within the basic multicellular unit, governed by the RANK/RANKL/osteoprotegerin and canonical Wnt signaling axes. The initiating lesion of osteoporosis is disruption of this coupling so that the resorption and formation arms are no longer balanced, regardless of whether the upstream driver is hormonal, pharmacological, or genetic.
Downstream
-
RANKL-Driven Osteoclastogenesis
Show evidence (2 references)
"During the bone remodelling cycle, osteoclastic resorption is tightly coupled to osteoblastic bone formation."
Establishes the normal tight coupling of resorption to formation whose disruption is the conserved initiating lesion of this module. Evidence source is OTHER because this is a review article.
"The key signalling pathways controlling osteoclastic bone resorption and osteoblastic bone formation are receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin and canonical Wnt signalling."
Identifies the conserved RANK/RANKL/OPG and Wnt signaling axes that govern the remodeling balance perturbed across osteoporoses. Evidence source is OTHER because this is a review article.
RANKL-Driven Osteoclastogenesis
amplifier
Loss of remodeling coupling shifts the RANKL/OPG ratio toward RANKL, the critical uncoupling factor that drives differentiation and survival of osteoclasts from myeloid precursors. Estrogen deficiency raises RANKL and lowers OPG; glucocorticoid excess likewise enhances RANKL and suppresses OPG, converging on enhanced osteoclastogenesis.
Downstream
-
Increased Osteoclastic Bone Resorption
Show evidence (2 references)
"Nuclear factor-κβ ligand (RANKL) appears to be the critical uncoupling factor that enhances osteoclastogenesis. In contrast, osteoprotegerin (OPG) is a RANKL antagonist secreted by osteoblast lineage cells."
Directly names RANKL as the critical uncoupling factor enhancing osteoclastogenesis and OPG as its antagonist, the conserved amplifier step. Evidence source is OTHER because this is a review article.
"Estrogen deficiency leads to the uncoupling of bone resorption and formation; therefore, resulting in greater bone loss."
Shows that a major upstream driver (estrogen deficiency) acts through uncoupling resorption from formation, the mechanism this node captures. Evidence source is OTHER because this is a review article.
Increased Osteoclastic Bone Resorption
central effector
Expanded and activated osteoclasts digest mineralized bone matrix at a rate that exceeds osteoblastic replacement. This is the central effector step of the module: resorption that is normally balanced by an equal wave of formation now outpaces it, eroding trabecular and cortical bone.
Downstream
-
Impaired Osteoblastic Bone Formation
Show evidence (2 references)
"Bone remodeling involves the removal of mineralized bone by osteoclasts followed by the formation of bone matrix through the osteoblasts that subsequently become mineralized."
Establishes osteoclast-mediated removal of mineralized bone as the resorptive arm of remodeling whose excess defines this central effector step. Evidence source is OTHER because this is a review article.
"the processes of bone resorption and formation are tightly coupled allowing a wave of bone formation to follow each cycle of bone resorption, thus maintaining skeletal integrity."
Describes how resorption is normally coupled to a following wave of formation; loss of this coupling yields the net resorption this node represents. Evidence source is OTHER because this is a review.
Net Bone Loss and Skeletal Fragility
consequence
Sustained imbalance between excess resorption and deficient formation produces net negative bone balance, loss of bone mineral density, and deterioration of trabecular and cortical microarchitecture. The accumulated structural deficit reduces bone strength and predisposes to low-trauma fractures, the defining clinical consequence of osteoporosis.
Show evidence (2 references)
"Disruption of the bone remodelling cycle and any resulting imbalance between bone resorption and formation leads to metabolic bone disease, most commonly osteoporosis."
Directly states that imbalance between resorption and formation leads to osteoporosis, the defining consequence of this module. Evidence source is OTHER because this is a review article.
"Osteoporosis resulting from an imbalance of bone turnover between resorption and formation is a critical health issue worldwide."
Confirms that osteoporosis is the clinical outcome of imbalanced bone turnover, the endpoint of this module's causal chain. Evidence source is OTHER because this is a review article.